The US biotech landscape is rapidly evolving, with data scientists at its core. This article delves into the future of data science in US biotech by 2026, outlining critical opportunities, essential skills, and how professionals can prepare for this dynamic field.

The year 2026 marks a significant turning point in the pharmaceutical industry with the patent expiration of seven blockbuster drugs. This presents unique investment opportunities in generic and biosimilar manufacturers, as well as for innovative companies poised to fill market gaps. Understand the financial implications and strategic moves for investors.